Molecular Atlas of Tau Boosts Precision in Neuro Care

New research challenges the "one-size-fits-all" approach to diagnosing and treating tauopathies.

Jan. 30, 2026 at 9:47pm

Got story updates? Submit your updates here. ›

Researchers at Boston Children's Hospital have developed a novel mass spectrometry tool called FLEXITau that enables the absolute quantification of pathological tau species across over 20 neurodegenerative diseases known as tauopathies. The findings provide a precise molecular roadmap for diagnostics and drug development, identifying 145 post-translational modifications and 195 cleavage sites on tau protein.

Why it matters

The current approach to diagnosing and treating tauopathies, which include Alzheimer's disease and chronic traumatic encephalopathy (CTE), has been a "one-size-fits-all" model. This new research challenges that approach by providing a detailed molecular atlas of tau that can enable more precise diagnostics, imaging, and therapeutics for these devastating neurological conditions.

The details

The research team, led by senior authors Judith A. Steen, PhD, and Hanno Steen, PhD, analyzed brain tissue from 203 patients spanning several tauopathies. Using the FLEXITau tool, they were able to measure the identities and abundances of disease-relevant chemical modifications on tau protein. Machine learning models then ranked the molecular features that best distinguished each disease based on these quantified chemical changes. The findings suggest that distinct enzymatic "writer" and "eraser" pathways drive tau pathology in different diseases, opening new avenues for targeted therapeutics.

  • The research was published on January 31, 2026.

The players

Judith A. Steen

PhD, senior author and Director of the Neuroproteomics Laboratory at Boston Children's Hospital.

Hanno Steen

PhD, senior author and researcher at Boston Children's Hospital.

Mukesh Kumar

PhD, co-first author of the study.

Christoph N. Schlaffner

PhD, co-first author of the study.

Shaojun Tang

PhD, co-first author of the study.

Got photos? Submit your photos here. ›

What they’re saying

“For the first time, we can tell diagnostics and drug developers exactly which post-translational modifications to target across tauopathies, where they are on the protein, and how abundant they are in each disease.”

— Judith A. Steen, Director of the Neuroproteomics Laboratory at Boston Children's Hospital (Mirage News)

“The machine learning analysis ranks modifications by importance to disease. This provides a priority list for diagnostics and drug development—the modifications that matter most.”

— Judith A. Steen, Director of the Neuroproteomics Laboratory at Boston Children's Hospital (Mirage News)

“Knowing how much of a molecular target exists is essential for diagnostic or drug design. If a modification is rare or low abundance, it's not a viable target. FLEXITau gives us the quantitative data needed to model dosing, pharmacokinetics, and therapeutic feasibility.”

— Judith A. Steen, Director of the Neuroproteomics Laboratory at Boston Children's Hospital (Mirage News)

What’s next

The findings from this study provide a foundation for precision diagnostics, imaging, and therapeutics across tau-mediated neurodegeneration. The FLEXIQuant platform developed can also be extended to study other proteins of interest in neurodegeneration and other diseases.

The takeaway

This research represents a significant advancement in our understanding of tau protein aggregation, a shared feature in over 20 neurodegenerative diseases. By providing a detailed molecular atlas of tau, it challenges the current "one-size-fits-all" approach and paves the way for more precise, targeted diagnostics and treatments for these devastating conditions.